Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 11/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10668024 | 0.83 | LMNA (0.47) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL4757989 | 0.80 | GRM2 (0.46) | GRM2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL10888984 | 0.79 | HPGD (0.55) | GRM2ALDH1A1ADORA3ADORA2AHPGD | |
| SCHEMBL2878149 | 0.79 | TSHR (0.47) | GRM2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL4757995 | 0.79 | HSD17B10 (0.42) | ALDH1A1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL4790589 | 0.77 | POLB (0.45) | GRM2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL4757994 | 0.75 | GRM2 (0.49) | GRM2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL4759824 | 0.74 | GRM2 (0.43) | GRM2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL9475577 | 0.73 | HPGD (0.52) | GRM2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL4759867 | 0.72 | NPC1 (0.47) | NPC1RAB9AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470698-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2007-10-25 | — | — | US | disclosed |
| US-7271171-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060040959-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-02-23 | — | — | US | disclosed |
| EP-1499614-A4 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6921825-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICUALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1499614-A1 | ADENOSINE A3 RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003095457-A1 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| US-20030144266-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6448253-B1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6407236-B1 | TUMOR DIAGNOSIS; ANTIINFLAMMATORY AGENTS; ANTIISCHEMIC AGENTS; ANTIDEPRESSANTS | MEDCO RESEARCH, INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2000015231-A9 | ADENOSINE A3 RECEPTOR MODULATORS | MEDCO RES INC (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000015231-A1 | ADENOSINE A3 RECEPTOR MODULATORS | MEDCO RESEARCH INC. (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-1995001356-A1 | 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES HAVING ANTAGONISTIC ACTIVITY ON ADENOSINE A2 RECEPTOR | SCHERING-PLOUGH S.P.A. (IT) | 1995-01-12 | — | — | WO | disclosed |
| US-5204353-A | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith | CIBA-GEIGY CORPORATION (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0288431-B1 | 3H-1,2,3-triazolo[4,5-d]pyrimidines | CIBA-GEIGY AG (CH) | 1992-08-19 | — | — | EP | disclosed |
| EP-0288431-A1 | 3H-1,2,3-triazolo[4,5-d]pyrimidines | CIBA-GEIGY AG (CH) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040959-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | GRM2 1018/4885NPC1 2985/4885RAB9A 1531/4885 |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | ADORA3, ADORA2A, ADORA1 | GRM2 1018/4885NPC1 2985/4885RAB9A 1531/4885 |
| US-20030144266-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | GRM2 852/4885NPC1 2745/4885RAB9A 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.